The leronlimab 350 mg dose versus placebo comparison for

New Post Public Reply Private Reply Replies (1) Message Board
TechGuru
805
Quote:
The leronlimab 350 mg dose versus placebo comparison for the primary endpoint PDFF was statistically significant. Leronlimab compared to placebo also reached near significance for the secondary endpoint cT1.


So the results for 350mg (part 2, open-label are significant for primary (PDFF) and close for secondary.

This is good. What is needed is the topline report and the 700mg numbers of part one. My guess is that the CCR5 haplotype information is going to be brought to bear in order to understand the 700mg - 350mg differences (and 700 mg results).

Hopefully we will get the number soon to better understand.

In light of the humongous potential market for NASH any news can arguably be good news for the million of patients.

We need the top-line report !!! and ... go 700 mg , Go !!!

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Dell Technologies: A Fresh Look at Investor Sentiment Trends

Updated Category News Views 285

Understanding Investor Sentiment for Dell Technologies Dell Technologies's recent report provides insight into the company's short interest metrics, illustrating a decline of 14.71%. Currently, 17.41 million shares are sold short, which represents about 5.8% of the company's available shares for trading. With an average trading volume indicating it would take 2.78 days to...

Continue Reading
Compass Diversified Faces Investigation for Securities Violations

Updated Category News Views 173

Compass Diversified Investigates Securities Fraud Claims Compass Diversified (NYSE: CODI) is currently facing serious allegations relating to violations in securities laws. An investigation has been initiated to determine the validity of these claims and how they may affect investors. This situation has raised alarms in the investment community as stakeholders seek...

Continue Reading
Understanding the Dow Inc. Class Action Lawsuit Opportunities

Updated Category News Views 226

Understanding the Dow Inc. Class Action Lawsuit Opportunities Investors in Dow Inc. (NYSE: DOW) have a significant opportunity to take action due to a recent class action lawsuit against the company. This legal movement stems from allegations regarding Dow's disclosure practices and possible financial mismanagement. People who purchased or acquired securities within a...

Continue Reading
Growth Prospects of the Global Medical Imaging Reagents Market

Updated Category News Views 148

Overview of the Medical Imaging Reagents Market The medical imaging reagents market is on the verge of significant growth, projected to reach USD 19.31 billion by 2034. This growth, at a compound annual growth rate (CAGR) of 5.1%, reflects the increasing importance of imaging technologies in healthcare. Key Drivers of Market Growth Several factors are driving this...

Continue Reading
Mike Tyson Teams Up with GBank Financial in New Venture

Updated Category News Views 285

GBank Financial Holdings Inc. Welcomes Mike Tyson GBank Financial Holdings Inc. is excited to announce a significant partnership with the legendary Mike Tyson. This strategic collaboration marks a new chapter for GBank, as Tyson steps in as both a strategic investor and promotional partner for the innovative company, BoltBetz. This new partnership aims to revolutionize...

Continue Reading